Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma
Open accessThe DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
One-third of BRAF-mutant metastatic melanoma patients treated with combined BRAF and MEK inhibition progress within 6 months. Treatment options for these patients remain limited. Here we analyse 20 BRAF(V600)-mutant melanoma metastases derived from 10 patients treated with the combination of dabrafenib and trametinib for resistance mechanisms and genetic correlates of response. Resistance mechanisms are identified in 9/11 progressing tumours and MAPK reactivation occurred in 9/10 tumours, commonly via BRAF amplification and mutations activating NRAS and MEK2. Our data confirming that MEK2(C125S), but not the synonymous MEK1(C121S) protein, confers resistance to combination therapy highlight the functional differences between these kinases and the preponderance of MEK2 mutations in combination therapy-resistant melanomas. Exome sequencing did not identify additional progression-specific resistance candidates. Nevertheless, most melanomas carried additional oncogenic mutations at baseline (for example, RAC1 and AKT3) that activate the MAPK and PI3K pathways and are thus predicted to diminish response to MAPK inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In cell lines and xenografts, intrinsic and acquired resistance to signaling pathway inhibitors against estrogen, RAF, EGFR, PI3K, and others is sometimes associated with mutations in p16Ink4a, upregulated expression of cyclin D1 or other D-type cyclins, or upregulation of CDK4 or CDK6 (Jiang et al., 2016; Long et al., 2014; Yadav et al., 2014).”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Long et al., 2014
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
A framework for variation discovery and genotyping using next-generation DNA sequencing data
DePristo, M. A., Banks, E., Poplin, R., Garimella, K. V., Maguire, J. R., Hartl, C., Philippakis, A. A., del Angel, G., Rivas, M. A., Hanna, M., et al. (2011) · Nature Genetics · doi:10.1038/ng.806 · Cited by 11,456
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
A Third-Generation Lentivirus Vector with a Conditional Packaging System
Dull, T., Zufferey, R., Kelly, M., Mandel, R. J., Nguyen, M., Trono, D., & Naldini, L. (1998) · Journal of Virology · doi:10.1128/jvi.72.11.8463-8471.1998 · Cited by 3,341
Patterns of somatic mutation in human cancer genomes
Greenman, C., Stephens, P., Smith, R., Dalgliesh, G. L., Hunter, C., Bignell, G., Davies, H., Teague, J., Butler, A., Stevens, C., et al. (2007) · Nature · doi:10.1038/nature05610 · Cited by 3,080
Self-citationCombined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Self-citationA landscape of driver mutations in melanoma
Hodis, E., Watson, I. R., Kryukov, G. V., Arold, S. T., Imielinski, M., Theurillat, J.-P., Nickerson, E., Auclair, D., Li, L., Place, C., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.024 · Cited by 2,610
Cited by
Items 101–200 of 380
Gallagher, S. J., Gunatilake, D., Beaumont, K. A., Sharp, D. M., Tiffen, J. C., Heinemann, A., Weninger, W., Haass, N. K., Wilmott, J. S., Madore, J., et al. (2017) · International Journal of Cancer · doi:10.1002/ijc.31199 · Cited by 60
Self-citationMITF Expression Predicts Therapeutic Vulnerability to p300 Inhibition in Human Melanoma
Kim, E. J., Zucconi, B. E., Wu, M., Nocco, S. E., Meyers, D. J., McGee, J. S., Venkatesh, S., Cohen, D. L., Gonzalez, E. C., Ryu, B., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2331 · Cited by 56
Taking advantage of drug resistance, a new approach in the war on cancer
Wang, L., & Bernards, R. (2018) · Frontiers of Medicine · doi:10.1007/s11684-018-0647-7 · Cited by 53
Aaroe, A., Kurzrock, R., Goyal, G., Goodman, A. M., Patel, H., Ruan, G. J., Ulaner, G. A., Young, J., Li, Z., Dustin, D. J., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022009013 · Cited by 52
“These data suggest that, unlike common solid tumors, such as melanoma, patients with ECD/RDD treated with trametinib are not prone to the development of adaptive resistance within the first few months or years of therapy; however, the optimal duration of therapy and the risk of recurrence/progression upon treatment di…”
BackgroundResearch progress of MEK1/2 inhibitors and degraders in the treatment of cancer
Wang, C., Wang, H., Zheng, C., Liu, Z., Gao, X., Xu, F., Niu, Y., Zhang, L., & Xu, P. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113386 · Cited by 51
The landscape of BRAF transcript and protein variants in human cancer
Marranci, A., Jiang, Z., Vitiello, M., Guzzolino, E., Comelli, L., Sarti, S., Lubrano, S., Franchin, C., Echevarría-Vargas, I. M., Tuccoli, A., et al. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0645-4 · Cited by 55
Ortiz‐Cuaran, S., Mezquita, L., Swalduz, A., Aldea, M. D., Mazières, J., Léonce, C., Jovelet, C., Pradines, A., Avrillon, V., Flores, W. R. C., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1037 · Cited by 53
“For cases presenting concurrent K/NRAS and PIK3CA mutations at PD (e.g., P57), preclinical evidence in melanoma PDXs suggests that triple combination encorafenib/binimetinib/BKM120 or double combination VX-11e/BKM120 could improve tumor growth control (40).”
BackgroundResultInfluentialMechanistic model of MAPK signaling reveals how allostery and rewiring contribute to drug resistance
Fröhlich, F., Gerosa, L., Muhlich, J. L., & Sorger, P. K. (2023) · Molecular Systems Biology · doi:10.15252/msb.202210988 · Cited by 55
“0 to Other Resistance Mechanisms NRASQ61K is a frequently observed resistance mutations found in melanoma patients treated with RAF/MEK therapy (Long et al, 2014; Shi et al, 2014).”
BackgroundCirculating Tumor DNA Allows Early Treatment Monitoring in BRAF- and NRAS-Mutant Malignant Melanoma
Braune, J., Keller, L., Schiller, F., Graf, E., Rafei-Shamsabadi, D. A., Wehrle, J., Follo, M., Philipp, U., Hussung, S., Pfeifer, D., et al. (2020) · JCO Precision Oncology · doi:10.1200/po.19.00174 · Cited by 55
Huang, F., Cai, F., Dahabieh, M. S., Gunawardena, K., Talebi, A., Dehairs, J., El-Turk, F., Park, J. Y., Li, M., Gonçalves, C., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci166644 · Cited by 55
“25 Normalized and background-corrected microarray data (Kakavand 2017, Long 2014, and Rizos 2014) were downloaded from the Gene-Expression Omnibus public database, accession numbers GSE99898, GSE61992 and GSE50509 (40-42).”
Signaling and Immune Regulation in Melanoma Development and Responses to Therapy
Lin, W. M., & Fisher, D. E. (2016) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-052016-100208 · Cited by 52
Dabrafenib plus Trametinib: a Review in Advanced Melanoma with a BRAF V600 Mutation
Dhillon, S. (2016) · Targeted Oncology · doi:10.1007/s11523-016-0443-8 · Cited by 50
Biology and Treatment of BRAF Mutant Metastatic Melanoma
Kong, B. Y., Carlino, M. S., & Menzies, A. M. (2016) · Melanoma Management · doi:10.2217/mmt.15.38 · Cited by 46
Self-citationLiu, S., Zou, B., Tian, T., Luo, X., Mao, B., Zhang, X., & Lei, H. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28032 · Cited by 44
“It has been already discovered that MAPK reactivation is increased in drug resistance to early treatment of BRAF‐mutant metastatic melanoma.(33) Similarly, MAPK signaling is suppressed to increase drug sensitivity in colon cancer cells.”
BackgroundEffective Treatment of Metastatic Melanoma by Combining MAPK and PI3K Signaling Pathway Inhibitors
Aasen, S. N., Parajuli, H., Hoang, T., Feng, Z., Stokke, K., Wang, J., Roy, K., Bjerkvig, R., Knappskog, S., & Thorsen, F. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174235 · Cited by 49
“MAPK inhibition has previously been associated with acquired treatment resistance [18].”
BackgroundMicroRNAs as Key Players in Melanoma Cell Resistance to MAPK and Immune Checkpoint Inhibitors
Motti, M. L., Minopoli, M., Carluccio, G. D., Ascierto, P. A., & Carriero, M. V. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124544 · Cited by 62
“Unfortunately, patients treated with dabrafenib/trametinib combination therapy also develop alterations in the same genes that support single-agent resistance including MEK1/2 mutations, BRAF amplification, BRAF alternative splicing, and NRAS mutations [12,13].”
BackgroundLiquid Biopsy in Melanoma: Significance in Diagnostics, Prediction and Treatment Monitoring
Kamińska, P., Buszka, K., Zabel, M., Nowicki, M. O., Alix‐Panabières, C., & Budna, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189714 · Cited by 53
“Despite BRAF inhibition, the MAPK pathway can be activated due to mutations in the NRAS gene, promoting tumor survival [161].”
BackgroundHu, J., Wei, J., Yim, H., Wang, L., Xie, L., Jin, M. S., Kabir, M., Qin, L., Chen, X., Liu, J., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01609 · Cited by 43
Crystal structure of ERK2 G169D mutant
Yin, J., Jaiswal, B. S., & Wang, W. (2018) · Worldwide Protein Data Bank · doi:10.2210/pdb6d5y/pdb · Cited by 42
Trametinib in the treatment of melanoma
Thota, R., Johnson, D. B., & Sosman, J. A. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1026323 · Cited by 52
“Although the initial responses are more prolonged with the combination of BRAF and MEK inhibition (~ 9 -- 11 months), acquired resistance still occurs and usually involves MAPK reactivation [20,21].”
BackgroundAbravanel, D. L., Nishino, M., Sholl, L. M., Ambrogio, C., & Awad, M. M. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.03.026 · Cited by 42
Kosnopfel, C., Sinnberg, T. W., Sauer, B., Niessner, H., Schmitt, A., Makino, E., Forschner, A., Hailfinger, S., Garbe, C., & Schittek, B. (2017) · Oncotarget · doi:10.18632/oncotarget.16204 · Cited by 43
“With reactivation of ERK phosphorylation being a recurring theme both in resistance to BRAFV600E/K inhibitors and to the combination of BRAF and MEK inhibitors [7, 8, 12, 13], recent research focussed on inhibition of the MAPK signalling pathway further downstream.”
BackgroundMechanisms of Melanoma Progression and Treatment Resistance: Role of Cancer Stem-like Cells
Hmada, Y. A., Brodell, R. T., Kharouf, N., Flanagan, T. W., AlAmodi, A. A., Hassan, S.-Y., Shalaby, H., Hassan, S.-L., Haïkel, Y., Megahed, M., et al. (2024) · Cancers · doi:10.3390/cancers16020470 · Cited by 48
“The most mutated genes, which are associated with the development of resistance to targeted therapy in melanoma include CDKN2A [92,93], RB1 [92,94], PIK3CA, AKT3, HOXD8 [95], PAX5 [93], MAP3K8 [96], and MITF [95].”
BackgroundGupta, R., Bugide, S., Wang, B., Green, M. R., Johnson, D. B., & Wajapeyee, N. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1821889116 · Cited by 47
“Previous studies have indicated that the majority of BRAFi-acquired resistance results from activation of the MAPK pathway by various mechanisms (11, 12, 21, 22).”
BackgroundKim, T., Havighurst, T. C., Kim, K., Albertini, M. R., Xu, Y. G., & Spiegelman, V. S. (2018) · Molecular Carcinogenesis · doi:10.1002/mc.22786 · Cited by 38
“trametinib, respectively, increases the efficacy over single treatment, but resistance to combination therapy still arises.(13) We wanted to test whether vemurafenib-resistant cell line is sensitive to dabrafenib and”
BackgroundCirculating Tumor DNA Testing Opens New Perspectives in Melanoma Management
Sacco, A., Forgione, L., Carotenuto, M., Luca, A. D., Ascierto, P. A., Botti, G., & Normanno, N. (2020) · Cancers · doi:10.3390/cancers12102914 · Cited by 43
“Q61K/R), in acquired resistance to dabrafenib/trametinib combination therapy in BRAF-mutant metastatic melanoma patients [72].”
BackgroundEpigenetic Mechanisms of Escape from BRAF Oncogene Dependency
Khaliq, M., & Fallahi‐Sichani, M. (2019) · Cancers · doi:10.3390/cancers11101480 · Cited by 43
Sasame, J., Ikegaya, N., Kawazu, M., Natsumeda, M., Hayashi, T., Isoda, M., Satomi, K., Tomiyama, A., Oshima, A., Honma, H., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3622 · Cited by 38
BRAF internal deletions and resistance to BRAF / MEK inhibitor therapy
Johnson, D. B., Childress, M. A., Chalmers, Z. R., Frampton, G. M., Ali, S. M., Rubinstein, S. M., Fabrizio, D. A., Ross, J. S., Balasubramanian, S., Miller, V. A., et al. (2017) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12674 · Cited by 42
“Several elegant studies have demonstrated that resistance to combination therapy is driven by multiple mechanisms functioning in concert, supporting this notion (Long et al., 2014; Moriceau et al., 2015; Villanueva et al., 2013; Wagle et al., 2014).”
BackgroundResultWoo, P. Y. M., Lam, T., Pu, J. K.-S., Li, L., Leung, R. C. Y., Ho, J. M. K., Zhung, J. T. F., Wong, B., Chan, T. S. K., Loong, H. H.-F., et al. (2019) · Oncotarget · doi:10.18632/oncotarget.26932 · Cited by 37
“The first category is BRAF gene amplification[29].”
Izquierdo, E., Carvalho, D. M., Mackay, A. G., Temelso, S., Boult, J. K. R., Pericoli, G., Fernandez, E., Das, M., Molinari, V., Grabovska, Y., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0930 · Cited by 47
“However, acquired resistance was observed in patients under BRAF and MEK inhibitors, with the identification of MEK1 and MEK2 (MAP2K2) mutations as two of the main mechanisms (31,37-40).”
P21‐activated kinase 1 regulates resistance to BRAF inhibition in human cancer cells
Babagana, M., Johnson, S., Slabodkin, H., Bshara, W., Morrison, C., & Kandel, E. (2017) · Molecular Carcinogenesis · doi:10.1002/mc.22611 · Cited by 37
“In accordance with the theory that MAP kinase cascade activation is the key oncogenic function of BRAF, multiple alternative means of maintaining high ERK activity have been shown to circumvent BRAF inhibition in vitro and in vivo [23,29-31].”
Stagni, C., Zamuner, C., Elefanti, L., Zanin, T., Bianco, P. D., Sommariva, A., Fabozzi, A., Pigozzo, J., Mocellin, S., Montesco, M. C., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1124 · Cited by 35
SIRT2 Contributes to the Resistance of Melanoma Cells to the Multikinase Inhibitor Dasatinib
Karwaciak, I., Sałkowska, A., Karaś, K., Sobalska‐Kwapis, M., Walczak‐Drzewiecka, A., Pułaski, Ł., Strapagiel, D., Dastych, J., & Ratajewski, M. (2019) · Cancers · doi:10.3390/cancers11050673 · Cited by 36
“Therefore, combination therapy with BRAF inhibitor and trametinib (MEK1/2 inhibitor) has improved clinical outcomes [79], but has not solved the problem of emerging resistance [80].”
BackgroundZhao, K., Lu, Y., Chen, Y., Cheng, J., & Zhang, W. (2020) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2020.06.004 · Cited by 35
Non-small-cell lung cancer: how to manage BRAF-mutated disease
Guaitoli, G., Zullo, L., Tiseo, M., Dankner, M., Rose, A. A. N., & Facchinetti, F. (2023) · Drugs in Context · doi:10.7573/dic.2022-11-3 · Cited by 37
Kim, S. S., Carvajal, R. D., Kim, M., & Yang, H. W. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112570 · Cited by 38
Stellettin B induces apoptosis in human chronic myeloid leukemia cells via targeting PI3K and Stat5
Chen, Y., Zhou, Q., Zhang, L., Zhong, Y., Fan, G., Zhang, Z., Wang, R., Jin, M., Qiu, Y., & Kong, D. (2017) · Oncotarget · doi:10.18632/oncotarget.15957 · Cited by 34
“Drug combination with lower doses might improve the therapeutic index while keeping low toxicity [26].”
BackgroundStrategies for Overcoming Resistance in Tumours Harboring BRAF Mutations
Obaid, N., Bedard, K., & Huang, W. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18030585 · Cited by 39
“These largely represented BRAF splice variants (29%) or BRAF gene amplification (8%) [75,76], however, secondary mutations in other genes in the RAS-RAF-MEK-ERK pathway, such as neuroblastoma RAS viral oncogene homologue (NRAS) [77], and MAPK/ERK kinase (MEK) [78,79] can lead to resistance to therapy.”
BackgroundYap1 Mediates Trametinib Resistance in Head and Neck Squamous Cell Carcinomas
Mudianto, T., Campbell, K. M., Webb, J., Zolkind, P., Skidmore, Z. L., Riley, R., Barnell, E. K., Ozgenc, I., Giri, T., Dunn, G. P., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-4179 · Cited by 33
“These include reactivation of the MAPK pathway (20), activation of parallel signaling pathways such as the PI3K-AKT-mTOR pathway (21), increased activation of the Src/FAK/STAT3 signaling axis (22, 23), and upregulation of the Hippo effector Yap1 (13, 14).”
BackgroundLebedev, T. D., Khabusheva, E., Mareeva, S. R., Ivanenko, K. A., Morozov, A. V., Spirin, P., Рубцов, П. М., Snezhkina, A. V., Kudryavtseva, A. V., Sorokin, M., et al. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102226 · Cited by 35
Efficient blockade of locally reciprocated tumor-macrophage signaling using a TAM-avid nanotherapy
Wang, S. J., Li, R., Ng, T. S. C., Luthria, G., Oudin, M. J., Prytyskach, M., Köhler, R. H., Weissleder, R., Lauffenburger, D. A., & Miller, M. A. (2020) · Science Advances · doi:10.1126/sciadv.aaz8521 · Cited by 36
“We used bulk gene expression data of pretreatment and progression BRAFV600-mutant melanoma biopsies from 10 patients (GSE61992) (24) and of 69 primary high- or low-grade OVCA biopsies with or without MAPK (BRAF/KRAS/ERBB2) mutations (GSE12172) (34).”
NRF2 Enables EGFR Signaling in Melanoma Cells
Kreß, J. K. C., Jessen, C., Marquardt, A., Hufnagel, A., & Meierjohann, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22083803 · Cited by 34
IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma
Patel, H. M., Mishra, R., Yacoub, N., Alanazi, S., Kilroy, M. K., & Garrett, J. T. (2021) · Cancers · doi:10.3390/cancers13225863 · Cited by 36
Advances in Melanoma: From Genetic Insights to Therapeutic Innovations
Valdez-Salazar, F., Rio, L. A. J.-D., Padilla‐Gutiérrez, J. R., Valle, Y., Muñóz-Valle, J. F., & Valdés‐Alvarado, E. (2024) · Biomedicines · doi:10.3390/biomedicines12081851 · Cited by 41
“This can be due to the genetic heterogeneity of the tumor, where cancer cells harbor genetic mutations that make them intrinsically resistant to drugs [145].”
BackgroundTelomere length and survival in primary cutaneous melanoma patients
Rachakonda, P. S., Srinivas, N., Mahmoudpour, S. H., García‐Casado, Z., Requena, C., Traves, V., Soriano, V., Cardelli, M., Pjanova, D., Molven, A., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-29322-9 · Cited by 36
Combination Therapies to Inhibit the RAF/MEK/ERK Pathway in Melanoma: We are not Done Yet
McArthur, G. A. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00161 · Cited by 34
Interaction of molecular alterations with immune response in melanoma
Sloane, R. A. S., Gopalakrishnan, V., Reddy, S. M., Zhang, X., Reuben, A., & Wargo, J. A. (2017) · Cancer · doi:10.1002/cncr.30681 · Cited by 33
BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity
Emery, C. M., Monaco, K., Wang, P., Balak, M. N., Freeman, A. K., Meltzer, J., Delach, S. M., Rakiec, D. P., Ruddy, D. A., Korn, J. M., et al. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0211 · Cited by 31
“Although datasets are small, mechanisms of resistance to combined BRAF andMEK inhibition appear to overlap with those of single-agent BRAF inhibition (3, 12, 13), with MEK1/2 mutations emerging as a common mechanism.”
BRAF inhibition causes resilience of melanoma cell lines by inducing the secretion of FGF1
Grimm, J., Hufnagel, A., Wobser, M., Borst, A., Haferkamp, S., Houben, R., & Meierjohann, S. (2018) · Oncogenesis · doi:10.1038/s41389-018-0082-2 · Cited by 34
Schmitt, M., Sinnberg, T. W., Nalpas, N., Maaß, A., Schittek, B., & Maček, B. (2019) · Molecular & Cellular Proteomics · doi:10.1074/mcp.ra119.001302 · Cited by 33
“0 Expression BeadChip as described in the original publications (41, 42).”
MethodSystemic therapy of metastatic melanoma: on the road to cure.
Bhatia, S., Tykodi, S. S., Lee, S. M., & Thompson, J. A. (2015) · PubMed · Cited by 39
Self-citationYaeger, R. D., McKean, M. A., Haq, R., Beck, J. T., Taylor, M. H., Cohen, J. E., Bowles, D. W., Gadgeel, S. M., Mihalcioiu, C. L. D., Papadopoulos, K. P., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0024 · Cited by 32
Seo, T., Noguchi, E., Yoshida, M., Mori, T., Tanioka, M., Sudo, K., Shimomura, A., Yonemori, K., Fujiwara, Y., & Tamura, K. (2020) · Case Reports in Oncological Medicine · doi:10.1155/2020/2518383 · Cited by 28
“Studies on the resistance mechanisms for BRAF and MEK inhibitors have shown secondary RAS mutations, including those of NRAS or KRAS, can contribute to the resistance development by increasing MAPK reactivation [24].”
BackgroundThe Genetic Evolution of Metastasis
Rogiers, A., Lobón, I., Spain, L. A., & Turajlic, S. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-3863 · Cited by 30
Targeting BRAF-mutant non-small cell lung cancer: Current status and future directions
Riudavets, M., Cascetta, P., & Planchard, D. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.05.014 · Cited by 32
Ding, L., Sun, L., Bu, M. T., Zhang, Y., Scott, L. N., Prins, R. M., Su, M. A., Lechner, M. G., & Hugo, W. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1176994 · Cited by 32
“Two microarray datasets of MAPKi-treated tumors were used as validation cohort (35, 36).”
BackgroundMethodAdvances in Circulating Tumor DNA Analysis
Perakis, S. O., Auer, M., Belic, J., & Heitzer, E. (2017) · Advances in clinical chemistry · doi:10.1016/bs.acc.2016.11.005 · Cited by 39
Effects of a novel Nodal-targeting monoclonal antibody in melanoma
Strizzi, L., Sandomenico, A., Margaryan, N. V., Focà, A., Sanguigno, L., Bodenstine, T. M., Chandler, G. S., Reed, D. W., Gilgur, A., Seftor, E. A., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6049 · Cited by 26
“To address the challenge of drug resistance, combinatory approaches are under investigation and initial results are showing some improvement in progression free survival compared to monotherapy [10]; however, even with this approach, reactivation of MAPK, for example, can lead to early resistance [11].”
PIM kinases as therapeutic targets against advanced melanoma
Shannan, B., Watters, A. K., Chen, Q., Mollin, S., Dörr, M., Meggers, E., Xu, X., Gimotty, P. A., Perego, M., Li, L., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10703 · Cited by 30
“Our analyses indicate that compared to the pre-treatment sample counterparts, PIM1 levels are found elevated in approximately half of the patients displaying progressive disease, more specifically in 12/21 paired samples in one dataset (GSE50509, [35]) (Figure 5C) and 4/9 paired samples in an additional dataset (GSE61…”
ResultSecondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells
Hamid, A. B., & Petreaca, R. C. (2020) · Cancers · doi:10.3390/cancers12040927 · Cited by 32
Pulmonary metastasectomy in the era of targeted therapy and immunotherapy
Bong, C. Y., Smithers, B. M., & Chua, T. C. (2021) · Journal of Thoracic Disease · doi:10.21037/jtd.2020.03.120 · Cited by 25
“Whilst theoretical inhibitory targets exist within the MAPK pathway and to its downstream targets like ERK and CDK4 (57), no current effective therapies exist for resistant clones.”
BackgroundKardos, G. R., Gowda, R., Dinavahi, S. S., Kimball, S. R., & Robertson, G. P. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00834 · Cited by 26
Flemington, V., Davies, E. J., Robinson, D. M., Sandin, L. C., Delpuech, O., Zhang, P., Hanson, L. L., Farrington, P. M., Bell, S., Falenta, K., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0002 · Cited by 24
“Resistance continues to emerge through RAS/MAPK in this setting predominantly through BRAF amplification and mutations in NRAS, KRAS, NF1 and MEK [11, 12, 36, 37].”
BackgroundGao, M., Wang, H., Chen, X., Cao, W.-T., Li, F., Li, Y., Quan, H., Xie, C., & Lou, L. (2018) · Acta Pharmacologica Sinica · doi:10.1038/s41401-018-0020-z · Cited by 30
“Several mechanisms responsible for the acquired resistance to BRAF- or MEK-targeted agents have been reported, including feedback reactivation of the MAPK pathway [14] and activation of parallel signaling pathways [15–17].”
Olbryt, M., Pigłowski, W., Rajczykowski, M., Pfeifer, A., Student, S., & Fiszer-Kierzkowska, A. (2020) · Targeted Oncology · doi:10.1007/s11523-020-00695-0 · Cited by 28
Signaling pathways governing the behaviors of leukemia stem cells
Azizidoost, S., Nasrolahi, A., Sheykhi-Sabzehpoush, M., Anbiyaiee, A., Khoshnam, S. E., Farzaneh, M., & Shahab Uddin, M. S. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2023.01.008 · Cited by 31
“Downstream targets of the mitogen-activated protein kinase (MAPK) signaling, including ERK, JNK, and P38 have been implicated in tumor development.(215,216) Highly-expressed survivin has been reported in CD34þ/CD38 AML-LSCs and paired CD34þ AML patients.”
BackgroundPupo, G. M., Boyd, S. C., Fung, C., Carlino, M. S., Menzies, A. M., Pedersen, B., Johansson, P. A., Hayward, N. K., Kefford, R. F., Scolyer, R. A., et al. (2017) · Biomarker Research · doi:10.1186/s40364-017-0098-3 · Cited by 25
“Consequently, BRAF-mutant metastatic melanoma patients treated with combination BRAF and MEK inhibitors, rarely develop resistance due to alternate BRAF splicing [11].”
BackgroundSelf-citationDreyer, F. S., Cantone, M., Eberhardt, M., Jaitly, T., Walter, L. M., Wittmann, J., Gupta, S. K., Khan, F. M., Wolkenhauer, O., Pützer, B. M., et al. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.01.020 · Cited by 25
Liang, J., Yu, D., Luo, C., Bennett, C. F., Jedrychowski, M. P., Gygi, S. P., Widlund, H. R., & Puigserver, P. (2023) · Nature Communications · doi:10.1038/s41467-023-38968-7 · Cited by 33
Mai, R., Zhou, S., Zhong, W., Rong, S., Cong, Z., Li, Y., Xie, Q., Chen, H., Li, X., Liu, S., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4375 · Cited by 25
“Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant MM has been identified commonly via BRAF amplification and mutations activating NRAS and MEK2 [28].”
BackgroundProfiling networks of distinct immune-cells in tumors
Clancy, T., & Hovig, E. J. (2016) · BMC Bioinformatics · doi:10.1186/s12859-016-1141-3 · Cited by 22
“These patients consisted of progressing (acquired resistant) and matched pre-treatment melanoma tumor samples [50] treated with combined dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor).”
BackgroundActivity-Based Protein Profiling Shows Heterogeneous Signaling Adaptations to BRAF Inhibition
Sharma, R., Smalley, I., Spence, P., Sondak, V. K., Smalley, K. S. M., & Koomen, J. M. (2016) · Journal of Proteome Research · doi:10.1021/acs.jproteome.6b00613 · Cited by 21
“(12-18) Similar mechanisms of resistance have been observed between patients failing BRAFi monotherapy and the BRAFi-MEKi combinations.(19, 20) To date, attempts to understand the mechanisms underlying BRAFi resistance have centered upon genomic assessment, which can be complemented with additional information about t…”
BackgroundPeh, J., Boudreau, M. W., Smith, H. M., & Hergenrother, P. J. (2018) · Cell chemical biology · doi:10.1016/j.chembiol.2018.05.008 · Cited by 29
“In cells treated with trametinib + ceritinib, a number of resistant clones were clearly visible, indicating the presence of ALKi + MEKi resistant H3122 cells (Figs.”
InfluentialKim, H. Y., Duong, J. K., Gonzalez, M., Long, G. V., Menzies, A. M., Rizos, H., Lim, S. Y., Lee, J., & Boddy, A. V. (2019) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-03780-y · Cited by 23
Self-citationBrammeld, J. S., Petljak, M., Martincorena, I., Williams, S. P., García‐Alonso, L., Dalmases, A., Bellosillo, B., Robles‐Espinoza, C. D., Price, S., Barthorpe, S., et al. (2017) · Genome Research · doi:10.1101/gr.213546.116 · Cited by 27
“These mutations are all canonical driver mutations in tumorigenesis and known to activate oncogenic signaling and confer resistance to Cetuximab both experimentally and clinically (Diaz et al. 2012; Misale et al. 2012).”
Single-cell trajectories of melanoma cell resistance to targeted treatment
Schmidt, M., Mortensen, L. S., Loeffler‐Wirth, H., Kosnopfel, C., Krohn, K., Binder, H., & Kunz, M. (2021) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2021.0267 · Cited by 28
Anaplastic Lymphoma Kinase Confers Resistance to BRAF Kinase Inhibitors in Melanoma
Janoštiak, R., Malvi, P., & Wajapeyee, N. (2019) · iScience · doi:10.1016/j.isci.2019.06.001 · Cited by 25
Src-Dependent DBL Family Members Drive Resistance to Vemurafenib in Human Melanoma
Feddersen, C. R., Schillo, J. L., Varzavand, A., Vaughn, H. R., Wadsworth, L. S., Voigt, A. P., Zhu, E. Y., Jennings, B. M., Mullen, S. A., Bobera, J., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0244 · Cited by 29
Park, B.-S., Jeon, H., Kim, Y., Kwon, H., Choi, G.-E., Chi, S.-G., Park, H.-M., Lee, H., & Kim, T. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02031-w · Cited by 25
“Gene Expression Omnibus (GEO) data with BRAFi or BRAFi + MAPKi treated melanoma patient cohort (GSE65185 [5], GSE61992 [33]) were analyzed after quantile normalization using preprocessCore (v1.”
BackgroundMethodTumor Cell Resistance to the Inhibition of BRAF and MEK1/2
Chen, W., & Park, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914837 · Cited by 22
“Interestingly, MEK1 mutations were detected at a lower frequency in these studies, and only MEK2 C125S , but not the synonymous MEK1 C121S , conferred resistance to the D/T combination [39,40].”
InfluentialPuyalto, A., Rodríguez‐Remírez, M., López, I., Macaya, I., Guruceaga, E., Olmedo, M., Vilalta, A., Welch, C., Sandiego, S., Vicent, S., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-01991-3 · Cited by 22
“One of the best characterized mechanisms involves the reactivation of the MAPK pathway [59, 60].”
BackgroundMitogen-Activated Protein Kinase Signaling Pathway in Cutaneous Melanoma: An Updated Review
Acosta, A. M., & Kadkol, S. S. (2016) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2015-0475-rs · Cited by 21
BRAF V600E mutation is a potential therapeutic target for a small subset of synovial sarcoma
Watanabe, S., Shimomura, A., Kubo, T., Sekimizu, M., Seo, T., WATANABE, S.-I. I., Kawai, A., Yamamoto, N., Tamura, K., Kohno, T., et al. (2020) · Modern Pathology · doi:10.1038/s41379-020-0530-3 · Cited by 25
“NRAS mutation is a known cause of resistance to BRAF/MEK inhibition in melanoma and non-small cell lung carcinoma with BRAF mutation [36, 37], and this particular NRAS Q61K has been reported in 2–8% of BRAF-mutant melanoma cases resistant to single-agent BRAF inhibition [38–41] or combined BRAF/MEK inhibition [37].”
BackgroundTargeting p63 Upregulation Abrogates Resistance to MAPK Inhibitors in Melanoma
Patel, A. A., García, L. F., Mannella, V., Gammon, L., Borg, T., Maffucci, T., Scatolini, M., Chiorino, G., Vergani, E., Rodolfo, M., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3230 · Cited by 24
“However, despite initially impressive clinical responses, most patients with advanced melanoma treated with MAPK inhibitors develop acquired resistance within 6 to 7 months (3).”
BackgroundMolecular Basis of BRAF Inhibitor Resistance in Melanoma: A Systematic Review
Cosci, I., Salizzato, V., Fiore, P. D., Pigozzo, J., Guarneri, V., Mocellin, S., Ferlin, A., Mathlouthi, S., Piccin, L., & Garofalo, M. (2025) · Pharmaceuticals · doi:10.3390/ph18081235 · Cited by 32
Jeyaraj, G., Rajendran, A. K., Sathishkumar, K., Almutairi, B. O., Vadivelu, A., Chokkakula, S., Tu, Y., & Xie, W. (2025) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2025.1688455 · Cited by 25
Mutations in the Serine/Threonine Kinase BRAF: Oncogenic Drivers in Solid Tumors
Roa, P., Bremer, N. V., Foglizzo, V., & Cocco, E. (2024) · Cancers · doi:10.3390/cancers16061215 · Cited by 29
“As part of acquired resistance to BRAF inhibitors, emerging alterations in the BRAF gene itself can also occur [165].”
BackgroundHaugh, A. M., Salama, A. K. S., & Johnson, D. B. (2020) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2020.09.005 · Cited by 20
Potential Biomarkers of Skin Melanoma Resistance to Targeted Therapy—Present State and Perspectives
Olbryt, M. (2022) · Cancers · doi:10.3390/cancers14092315 · Cited by 21
“MAP2K1 (mutations: C121S, Q56P, V60E, P124L, G128V, V154L) MAPK activation Primary resistance; genetic analysis of samples and in vitro tests [22,24,27]”
BackgroundSkin Cancer Research Goes Digital: Looking for Biomarkers within the Droplets
Dobre, E.-G., Constantin, C., & Neagu, M. T. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12071136 · Cited by 20
Epigenetic Mechanisms Underlying Melanoma Resistance to Immune and Targeted Therapies
Rubanov, A., Berico, P., & Hernando, E. (2022) · Cancers · doi:10.3390/cancers14235858 · Cited by 25
“Downstream of BRAF, MEK1/2 gain-of-function mutations [24,25] and increased levels of COT1, a MAPK kinase activating MEK1, also enable therapy resistance [26].”
BackgroundA patent review of RAF kinase inhibitors (2010–2018)
Man, R., Zhang, Y., Jiang, A.-Q., & Zhu, H. (2019) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2019.1651842 · Cited by 20
Er, A. B. B., Sheldrake, H. M., & Sutherland, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147946 · Cited by 20
“…determine active integrin-related pathways, parental and resistant A375 and SK-MEL28 cells were grown on fibrinogen-coated and non-coated plates, and gene expression levels were compared for the targets MAPK1, MAP2K1, MAPK3, RELA, RELB, p21, IKK α , HRAS, SMAD4, SMAD7, AKT1, PAI1, PDL1, and PD-1 .”
MethodPreclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor
Wichmann, J., Rynn, C., Friess, T., Petrig-Schaffland, J., Kornacker, M., Handl, C., Emmenegger, J., Eckmann, J., Herting, F., Frances, N., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2761 · Cited by 18
Rogiers, A., Wolter, P., & Bechter, O. E. (2017) · Melanoma Research · doi:10.1097/cmr.0000000000000320 · Cited by 18
Immunotherapy and targeted therapy in brain metastases: emerging options in precision medicine
Lazaro, T. T., & Brastianos, P. K. (2017) · CNS Oncology · doi:10.2217/cns-2016-0038 · Cited by 20
Song, X., Qi-hua, W., & Huo, R. (2017) · Pathology & Oncology Research · doi:10.1007/s12253-017-0334-z · Cited by 18
“Interestingly enough, melanoma cells can make use of various kinds of resistance mechanisms, such as the reactivation of mitogen-activated protein kinase (MAPK) signaling pathway [16] as well as aberrant activation of another signaling pathway, the Wnt signaling pathways [17, 18].”
RetractedAnalysis of the Whole-Exome Sequencing of Tumor and Circulating Tumor DNA in Metastatic Melanoma
Diefenbach, R. J., Lee, J., Strbenac, D., Yang, J. Y. H., Menzies, A. M., Carlino, M. S., Long, G. V., Spillane, A. J., Stretch, J. R., Saw, R. P. M., et al. (2019) · Cancers · doi:10.3390/cancers11121905 · Cited by 19
“appears to be the case, for instance, for BRAF V600E gene amplification, a common mediator of resistance to BRAF and MEK inhibitors [41], which also promotes proliferative arrest in the absence of MAPK inhibitors.”
BackgroundSelf-citationBack, J., Nguyen, M. N., Li, L., Lee, S., Lee, I., Chen, F., Gillinov, L. A., Chung, Y., Alder, K. D., Kwon, H., et al. (2021) · Bone Research · doi:10.1038/s41413-021-00158-w · Cited by 21
Metadata
- Authors
- Long, G. V., Fung, C., Menzies, A. M., Pupo, G. M., Carlino, M. S., Hyman, J., Shahheydari, H., Tembe, V., Thompson, J. F., Saw, R. P., Howle, J., Hayward, N. K., Johansson, P., Scolyer, R. A., Kefford, R. F., & Rizos, H.
- Affiliations
- The University of Sydney (AU)
- Royal Prince Alfred Hospital (AU)
- QIMR Berghofer Medical Research Institute (AU)
- Corresponding author
- Rizos, Helen
- ORCID
- Venue
- Nature Communications
- Published
- 2014-12-02
- Volume
- 5
- Issue
- 1
- Pages
- 5694-5694
- ISSN
- 2041-1723 (ISSN-L)
- OpenAlex
- W2003402062
- Cited by
- 375
- References
- 62
- Citations by year
- 2026: 16 · 2025: 21 · 2024: 27 · 2023: 44 · 2022: 26 · 2021: 35 · 2020: 36 · 2019: 33 · 2018: 33 · 2017: 43 · 2016: 34 · 2015: 24 · 2014: 1
- FWCI
- 13.92
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature Communications (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Westmead Millennium Institute for Medical Research
- Australian Cancer Research Foundation
- Cancer Institute NSW
- Melanoma Institute Australia
- Medical Research Council
- National Health and Medical Research Council (633004)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- dabrafenib, trametinib, combination therapy resistance, MAPK pathway reactivation, BRAF amplification, NRAS mutation, PI3K signaling, Rac1, AKT3, BRAF V600E mutation, resistance mechanisms
- MeSH terms
- Antineoplastic Combined Chemotherapy Protocols, Humans, Imidazoles, Melanoma, Membrane Proteins, Oximes, Pyridones, Pyrimidinones, Skin Neoplasms, Drug Resistance, Neoplasm, Phosphatidylinositol 3-Kinases, GTP Phosphohydrolases, rac1 GTP-Binding Protein, MAP Kinase Kinase 1, MAP Kinase Kinase 2, Proto-Oncogene Proteins B-raf, Proto-Oncogene Proteins c-akt
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.